Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

ASH 2019 MM

Almost 90% of patients responded to infusions of the LCAR B38M, and the majority of complete responders became minimal residual disease–negative.
Newly diagnosed patients receiving daratumumab/lenalidomide/dexamethasone achieved rapid and deep responses.
Positron emission tomography combined with computed tomography (PET/CT)/minimal residual disease–negativity concordance could be a predictive surrogate for patient outcomes.
For the first time, overall survival benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible multiple myeloma patients is confirmed.
After induction with daratumumab and CyBorD, maintenance daratumumab improves depth of response and survival in newly diagnosed and relapsed multiple myeloma.
Presented as a late-breaking abstract, CANDOR met its primary end point, showing that daratumumab/carfilzomib/dexamethasone significantly prolonged progression-free survival.
Responses were achieved by more than 90% of patients receiving JNJ-4528, and all patients tested for minimal residual disease (MRD) status were MRD-negative.
In an analysis of more than 10,000 relapsed/refractory patients treated in routine clinical practice with ixazomib/lenalidomide/dexamethasone, outcomes were as good as those reported in clinical trials.
Final analysis of patient-reported outcomes from the phase 3 ELOQUENT-2 trial confirms elotuzumab has no negative impact on health-related quality of life.
In patients with relapsed/refractory multiple myeloma, treatment with elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone shows encouraging responses, with manageable toxicity.
Page 1 of 2
Results 1 - 10 of 20